In addition, lung, colorectal, biliary tract, bladder, cervical, endometrial, ovarian, prostate, and pancreatic cancers may also overexpress HER2/neu protein in a substantial proportion of cases although routine testing is not performed in these cancers [2–7]. This evidence concerns the gene ERBB2 and pancreatic neoplasm.